These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 31450951)

  • 1. Design and monitoring of survival trials based on restricted mean survival times.
    Luo X; Huang B; Quan H
    Clin Trials; 2019 Dec; 16(6):616-625. PubMed ID: 31450951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and monitoring of survival trials in complex scenarios.
    Luo X; Mao X; Chen X; Qiu J; Bai S; Quan H
    Stat Med; 2019 Jan; 38(2):192-209. PubMed ID: 30281165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling and prediction of subject accrual and event times in clinical trials: a systematic review.
    Zhang X; Long Q
    Clin Trials; 2012 Dec; 9(6):681-8. PubMed ID: 22674642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Joint monitoring and prediction of accrual and event times in clinical trials.
    Zhang X; Long Q
    Biom J; 2012 Nov; 54(6):735-49. PubMed ID: 22907686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2013 Dec; 13():152. PubMed ID: 24314264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved survival modeling in cancer research using a reduced piecewise exponential approach.
    Han G; Schell MJ; Kim J
    Stat Med; 2014 Jan; 33(1):59-73. PubMed ID: 23900779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Irwin's restricted mean as an index for comparing survival in different treatment groups--interpretation and power considerations.
    Karrison TG
    Control Clin Trials; 1997 Apr; 18(2):151-67. PubMed ID: 9129859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monitoring event times in early phase clinical trials: some practical issues.
    Thall PF; Wooten LH; Tannir NM
    Clin Trials; 2005; 2(6):467-78. PubMed ID: 16422307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control-based imputation for sensitivity analyses in informative censoring for recurrent event data.
    Gao F; Liu GF; Zeng D; Xu L; Lin B; Diao G; Golm G; Heyse JF; Ibrahim JG
    Pharm Stat; 2017 Nov; 16(6):424-432. PubMed ID: 28834175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group sequential monitoring of years of life saved with paired censored survival data.
    Murray S
    Stat Med; 2002 Jan; 21(2):177-89. PubMed ID: 11782058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity to censored-at-random assumption in the analysis of time-to-event endpoints.
    Lipkovich I; Ratitch B; O'Kelly M
    Pharm Stat; 2016 May; 15(3):216-29. PubMed ID: 26997353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A useful design utilizing the information fraction in a group sequential clinical trial with censored survival data.
    Hsu CY; Chen CH; Hsu KN; Lu YH
    Biometrics; 2019 Mar; 75(1):133-143. PubMed ID: 30004574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design of non-inferiority randomized trials using the difference in restricted mean survival times.
    Weir IR; Trinquart L
    Clin Trials; 2018 Oct; 15(5):499-508. PubMed ID: 30074407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonparametric comparison of two survival functions with dependent censoring via nonparametric multiple imputation.
    Hsu CH; Taylor JM
    Stat Med; 2009 Feb; 28(3):462-75. PubMed ID: 18991250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dependent censoring in piecewise exponential survival models.
    Staplin ND; Kimber AC; Collett D; Roderick PJ
    Stat Methods Med Res; 2015 Jun; 24(3):325-41. PubMed ID: 25038073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple imputation based on restricted mean model for censored data.
    Liu LX; Murray S; Tsodikov A
    Stat Med; 2011 May; 30(12):1339-50. PubMed ID: 21560139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
    Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
    Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interim monitoring using the adaptively weighted log-rank test in clinical trials for survival outcomes.
    Yang S
    Stat Med; 2019 Feb; 38(4):601-612. PubMed ID: 30209818
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bias and precision of methods for estimating the difference in restricted mean survival time from an individual patient data meta-analysis.
    Lueza B; Rotolo F; Bonastre J; Pignon JP; Michiels S
    BMC Med Res Methodol; 2016 Mar; 16():37. PubMed ID: 27025706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.